ArticleERJ open research2021
What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance.
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).The European respiratory journal · 2023Pooled it
- Increasing physical activity in severe asthma: a systematic review and meta-analysis.The European respiratory journal · 2022Pooled it
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Key priorities to prevent avoidable asthma hospitalisations: insights from end-users.ERJ open research · 2026Article
- Effectiveness of Intravenous and Nebulized MgSOChildren (Basel, Switzerland) · 2025Review
- Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.The European respiratory journal · 2025Article
- Patient-centred outcomes in severe asthma: fatigue, sleep, physical activity and work.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) as Early Predictors of Biologic Response in Severe Asthma.Journal of asthma and allergy · 2025Article
- Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.Patient preference and adherence · 2025Article
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- The illness burden of severe asthma contrasted to people with mild-to-moderate asthma: a qualitative study.ERJ open research · 2024Article
- Patient education needs in severe asthma, a pilot study.BMC pulmonary medicine · 2024Article
- Outcome measures in asthma attack trials: can't see the good for the wheeze.ERJ open research · 2024Article
- Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma.Journal of asthma and allergy · 2024Article
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- Cough in chronic lung disease: a state of the art review.Journal of thoracic disease · 2023Review
- Definitions of non-response and response to biological therapy for severe asthma: a systematic review.ERJ open research · 2023Review
- What bothers severe asthma patients most? A paired patient-clinician study across seven European countries.ERJ open research · 2023Article
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.The European respiratory journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increasing number of new therapies for severe asthma; however, what outcomes people with severe asthma would like improved and what aspects they prioritise in new medications remain unknown. This study aimed to understand what outcomes are important to patients when prescribed new treatments and to determine the characteristics of importance to patients in their choice of asthma treatments. Participants with severe asthma (n=50) completed a cross-sectional survey that ranked 17 potential hypothetical outcomes of treatment using a seven-point Likert scale, as well as selecting their top five overall outcomes. Participants also completed hypothetical scenarios trading off medication characteristics for four hypothetical add-on asthma treatments. Participants (58% male), had a mean±sd age of 62.2±13.5 years. Their top three prioritised outcomes were: to improve overall quality of life (selected by 83% of people), reduce number and severity of asthma attacks (72.3%), and being able to participate in physical activity (59.6%) When trading off medication characteristics, the majority of patients with severe asthma chose the hypothetical medication with the best treatment efficacy (68%). However, a subgroup of patients prioritised the medication's side-effect profile and mode of delivery to select their preferred medication. People with severe asthma value improved quality of life as an important outcome of treatment. Shared decision-making discussions between clinicians and patients that centre around medication efficacy and side-effect profile can incorporate patient preferences for add-on therapy in severe asthma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.